Literature DB >> 24421546

Metformin: prevention and treatment of antipsychotic-induced weight gain.

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2013        PMID： 24421546      PMCID： PMC3857117          DOI： 10.1310/hpj4809-734

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  8 in total

Review 1.  Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.

Authors:  Samir Kumar Praharaj; Amlan Kusum Jana; Nishant Goyal; Vinod Kumar Sinha
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

2.  Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.

Authors:  Man Wang; Jian-hua Tong; Gang Zhu; Guang-ming Liang; Hong-fei Yan; Xiu-zhen Wang
Journal:  Schizophr Res       Date:  2012-03-05       Impact factor: 4.939

3.  Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.

Authors:  Ren-Rong Wu; Hua Jin; Keming Gao; Elizabeth W Twamley; Jian-Jun Ou; Ping Shao; Juan Wang; Xiao-Feng Guo; John M Davis; Philip K Chan; Jing-Ping Zhao
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

4.  Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.

Authors:  Jess G Fiedorowicz; Del D Miller; Jeffrey R Bishop; Chadi A Calarge; Vicki L Ellingrod; William G Haynes
Journal:  Curr Psychiatry Rev       Date:  2012-02-01

5.  Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.

Authors:  Trino Baptista; Nairy Rangel; Virginia Fernández; Edgardo Carrizo; Yamily El Fakih; Euderruh Uzcátegui; Tatiana Galeazzi; María A Gutiérrez; Mercedes Servigna; Adriana Dávila; Marycelvia Uzcátegui; Ana Serrano; Lisette Connell; Serge Beaulieu; Enma Araujo de Baptista
Journal:  Schizophr Res       Date:  2007-05-08       Impact factor: 4.939

Review 6.  Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments.

Authors:  Chandan Das; Guillermo Mendez; Sonal Jagasia; Lawrence A Labbate
Journal:  Ann Clin Psychiatry       Date:  2012-08       Impact factor: 1.567

7.  Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Authors:  Ren-Rong Wu; Jing-Ping Zhao; Xiao-Feng Guo; Yi-Qun He; Mao-Sheng Fang; Wen-Bin Guo; Jin-Dong Chen; Le-Hua Li
Journal:  Am J Psychiatry       Date:  2008-02-01       Impact factor: 18.112

8.  Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.

Authors:  Ren-Rong Wu; Jing-Ping Zhao; Hua Jin; Ping Shao; Mao-Sheng Fang; Xiao-Feng Guo; Yi-Qun He; Yi-Jun Liu; Jin-Dong Chen; Le-Hua Li
Journal:  JAMA       Date:  2008-01-09       Impact factor: 56.272
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.